Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
https://doi.org/10.4081/btvb.2026.442

Where cancer meets thrombosis: thrombo-inflammatory landscape of cancer-associated thrombosis

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Cancer, thrombosis, thrombo-inflammation

Authors

Victor Zibara
Department of Medicine, Division of Classical Hematology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.
Jeffrey I. Zwicker
zwickerj@mskcc.org
Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.

Cancer-associated thrombosis is a major contributor to morbidity and mortality among patients with cancer, significantly impacting both treatment strategies and the overall quality of life for these patients. The pathogenesis of thrombosis in cancer is multifactorial, involving intricate interactions between both host immune responses and tumor-derived factors. This review highlights several key immune-thrombotic pathways implicated in the development of cancer-associated thrombosis, including neutrophil activation and NETosis, monocyte/macrophage-mediated coagulation, and tumor-induced endothelial activation via inflammatory cytokines. A more profound understanding of these mechanisms is essential for refining risk stratification, developing targeted prophylactic strategies, and improving therapeutic management of cancer-associated thrombosis.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-4. DOI: https://doi.org/10.1111/j.1538-7836.2007.02374.x
2. Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137:1959-69. DOI: https://doi.org/10.1182/blood.2020007338
3. Mahajan A, Brunson A, Adesina O, et al. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv 2022;6:307-20. DOI: https://doi.org/10.1182/bloodadvances.2021005590
4. Hisada Y, Mackman N. Mechanisms of cancer-associated thrombosis. Res Pract Thromb Haemost 2023;7:100123. DOI: https://doi.org/10.1016/j.rpth.2023.100123
5. Sørensen HT, Mellemkjær L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50. DOI: https://doi.org/10.1056/NEJM200012213432504
6. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927-74. DOI: https://doi.org/10.1182/bloodadvances.2021004734
7. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013;122:1712-23. DOI: https://doi.org/10.1182/blood-2013-04-460121
8. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res 2013;131:S59-62. DOI: https://doi.org/10.1016/S0049-3848(13)70024-0
9. Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res 2015;135:S8-11. DOI: https://doi.org/10.1016/S0049-3848(15)50432-5
10. Hisada Y, Geddings JE, Ay C, Mackman N. Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost 2015;13:1372-82. DOI: https://doi.org/10.1111/jth.13009
11. Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological malignancies--a possible tumor-associated marker. J Cancer Res Clin Oncol 1986;111:54-8. DOI: https://doi.org/10.1007/BF00402777
12. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 2009;115:3919-23. DOI: https://doi.org/10.1002/cncr.24480
13. Khorana A, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7. DOI: https://doi.org/10.1182/blood-2007-10-116327
14. Pabinger I, Posch F. Flamethrowers: blood cells and cancer thrombosis risk. Hematology Am Soc Hematol Educ Program 2014;2014:410-7. DOI: https://doi.org/10.1182/asheducation-2014.1.410
15. Blix K, Jensvoll H, Brækkan SK, Hansen JB. White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø study. PLoS One 2013;8:e0073447. DOI: https://doi.org/10.1371/journal.pone.0073447
16. Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010;126:113-8. DOI: https://doi.org/10.1016/j.thromres.2010.05.012
17. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5. DOI: https://doi.org/10.1126/science.1092385
18. Hashimoto T, Ueki S, Kamide Y, et al. Increased circulating cell-free DNA in eosinophilic granulomatosis with polyangiitis: implications for eosinophil extracellular traps and immunothrombosis. Front Immunol 2022;12:801897. DOI: https://doi.org/10.3389/fimmu.2021.801897
19. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989;9:2752-5. DOI: https://doi.org/10.1128/mcb.9.6.2752-2755.1989
20. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017;130:1499-506. DOI: https://doi.org/10.1182/blood-2017-03-743211
21. Leal AC, Mizurini DM, Gomes T, et al. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep 2017;7:6438. DOI: https://doi.org/10.1038/s41598-017-06893-7
22. Joshita S, Nakazawa K, Sugiyama Y, et al. Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med 2009;48:687-91. DOI: https://doi.org/10.2169/internalmedicine.48.1900
23. Kaira K, Ishizuka T, Tanaka H, et al. Lung cancer producing granulocyte colony-stimulating factor and rapid spreading to peritoneal cavity. J Thorac Oncol 2008;3:1054-5. DOI: https://doi.org/10.1097/JTO.0b013e3181834f7b
24. Kawaguchi M, Asada Y, Terada T, et al. Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. Int J Clin Oncol 2010;15:191-5. DOI: https://doi.org/10.1007/s10147-010-0023-3
25. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012;10:136-44. DOI: https://doi.org/10.1111/j.1538-7836.2011.04544.x
26. Thomas GM, Brill A, Mezouar S, et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost 2015;13:1310-9. DOI: https://doi.org/10.1111/jth.13002
27. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010;107:15880-5. DOI: https://doi.org/10.1073/pnas.1005743107
28. Massberg S, Grahl L, Von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010;16:887-96. DOI: https://doi.org/10.1038/nm.2184
29. Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 2012;109:13076-81. DOI: https://doi.org/10.1073/pnas.1200419109
30. Herre M, Cedervall J, Mackman N, Olsson AK. Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases. Physiol Rev 2023;103:277-312. DOI: https://doi.org/10.1152/physrev.00062.2021
31. Wang Y, Li M, Stadler S, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol 2009;184:205-13. DOI: https://doi.org/10.1083/jcb.200806072
32. Cedervall J, Herre M, Dragomir A, et al. Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress. Oncoimmunology 2022;11:2049487. DOI: https://doi.org/10.1080/2162402X.2022.2049487
33. Rosell A, Aguilera K, Hisada Y, et al. Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer. Sci Rep 2021;11:5074. DOI: https://doi.org/10.1038/s41598-021-84476-3
34. Thålin C, Lundström S, Seignez C, et al. Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer. PLoS One 2018;13:e0191231. DOI: https://doi.org/10.1371/journal.pone.0191231
35. Mauracher LM, Posch F, Martinod K, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. J Thromb Haemost 2018;16:508-18. DOI: https://doi.org/10.1111/jth.13951
36. Gi T, Kuwahara A, Yamashita A, et al. Histopathological features of cancer-associated venous thromboembolism: presence of intrathrombus cancer cells and prothrombotic factors. Arterioscler Thromb Vasc Biol 2023;43:146-59. DOI: https://doi.org/10.1161/ATVBAHA.122.318463
37. Oklu R, Sheth RA, Wong KHK, et al. Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis. Cardiovasc Diagn Ther 2017;7:S140-9. DOI: https://doi.org/10.21037/cdt.2017.08.01
38. Thålin C, Aguilera K, Hall NW, et al. Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma. J Thromb Haemost 2020;18:2732-43. DOI: https://doi.org/10.1111/jth.15003
39. Jee J, Brannon AR, Singh R, et al. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism. Nat Med 2024;30:2499-507. DOI: https://doi.org/10.1038/s41591-024-03195-0
40. Mattox AK, Douville C, Wang Y, et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discov 2023;13:2166-79. DOI: https://doi.org/10.1158/2159-8290.CD-21-1252
41. Aleman MM, Gardiner C, Harrison P, Wolberg AS. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 2011;9:2251-61. DOI: https://doi.org/10.1111/j.1538-7836.2011.04488.x
42. Hohensinner PJ, Mayer J, Kirchbacher J, et al. Alternative activation of human macrophages enhances tissue factor expression and production of extracellular vesicles. Haematologica 2021;106:454-63. DOI: https://doi.org/10.3324/haematol.2019.220210
43. Lucotti S, Ogitani Y, Kenific CM, et al. Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell 2025;188:1642-61. DOI: https://doi.org/10.1016/j.cell.2025.01.025
44. Wilgenbus P, Pott J, Pagel S, et al. Coagulation proteases modulate nucleic acid uptake and cGAS-STING-IFN induction in the tumor microenvironment. JCI Insight 2025;10:e190311. DOI: https://doi.org/10.1172/jci.insight.190311
45. Wahab R, Hasan MM, Azam Z, et al. The role of coagulome in the tumor immune microenvironment. Adv Drug Deliv Rev 2023;200:115027. DOI: https://doi.org/10.1016/j.addr.2023.115027
46. Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. J Biol Chem 1997;272:27183-8. DOI: https://doi.org/10.1074/jbc.272.43.27183
47. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007;62:126-36. DOI: https://doi.org/10.1016/j.critrevonc.2007.01.001
48. Khorana AA, Barnard J, Wun T, et al. Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Adv 2022;6:1212-21. DOI: https://doi.org/10.1182/bloodadvances.2021005710
49. Malaponte G, Signorelli SS, Bevelacqua V, et al. Increased levels of NF-kB-dependent markers in cancer-associated deep venous thrombosis. PLoS One 2015;10:e0132496. DOI: https://doi.org/10.1371/journal.pone.0132496
50. Speiser W, Kapiotis S, Kopp CW, et al. Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies. Thromb Haemost 2001;85:362-7. DOI: https://doi.org/10.1055/s-0037-1615693
51. Brandtner AK, Lehner GF, Pircher A, et al. Differential procoagulatory response of microvascular, arterial and venous endothelial cells upon inflammation in vitro. Thromb Res 2021;205:70-80. DOI: https://doi.org/10.1016/j.thromres.2021.07.002
52. Dhar R, Dos Passos RR, Gower RM, et al. Toward targeting of inflammasome signaling in venous thrombosis. J Thromb Haemost 2025;23:3769-80. DOI: https://doi.org/10.1016/j.jtha.2025.08.032
53. Kansuttiviwat C, Niprapan P, Tantiworawit A, et al. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients. PLoS One 2023;18:e0279450. DOI: https://doi.org/10.1371/journal.pone.0279450
54. Reitter EM, Ay C, Kaider A, et al. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. Clin Exp Immunol 2014;177:253-60. DOI: https://doi.org/10.1111/cei.12308
55. Lim SH, Woo SY, Kim S, et al. Cross-sectional study of patients with diffuse large B-cell lymphoma: assessing the effect of host status, tumor burden, and inflammatory activity on venous thromboembolism. Cancer Res Treat 2016;48:312-21. DOI: https://doi.org/10.4143/crt.2014.266
56. Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res 2020;225:33-53. DOI: https://doi.org/10.1016/j.trsl.2020.06.012

How to Cite



1.
Zibara V, Zwicker JI. Where cancer meets thrombosis: thrombo-inflammatory landscape of cancer-associated thrombosis. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/442
Copyright (c) 2026 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.